Acceleron Pharma, Inc.

Merck & Co. is stopping its second Phase III trial of its pulmonary arterial hypertension drug Winrevair (sotatercept) in as many months due to confidence in the drug, this time in an earlier sett

Merck & Co., Inc. has received clearance for Winrevair (sotatercept) from the European Commission (EC) exactly five months after it was approved in the US, where the commercial launch to date has exc

Pharmaceutical manufacturers have been keen to invest in drugs that have potential in multiple diseases, paving the way for revenue growth through indication expansion. The phrase “pipeline-in-a-pill”

Merck & Co., Inc. ’s Winrevair (sotatercept) was approved by the US Food and Drug Administration for the treatment of pulmonary arterial hypertension, positioning the company to execute on its ambitio